Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer-Reference-Cited by-同舟云学术

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer

Published:2017-06-05 Issue:6 Volume:102 Page:997-1005
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Adiwijaya BS¹,Kim J¹,Lang I²,Csõszi T³,Cubillo A⁴,Chen J-S⁵,Wong M⁶,Park JO⁷,Kim JS⁸,Rau KM⁹,Melichar B¹⁰,Gallego JB¹¹,Fitzgerald J¹,Belanger B¹,Molnar I¹,Ma WW¹²

Affiliation:

1. Merrimack Pharmaceuticals, Inc.; Cambridge Massachusetts USA

2. National Institute of Oncology; Budapest Hungary

3. JNSZ Megyei Hetényi Géza Kórház Rendelöintézet; Szolnok Hungary

4. Centro Integral Oncológico Clara Campal; Madrid Spain

5. Chang Gung Memorial Hospital Linkou Branch; Taoyuan Taiwan

6. Westmead Hospital; Westmead Australia

7. Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul South Korea

8. Korea University Guro Hospital; Seoul South Korea

9. Chang Gung Memorial Hospital Kaohsiung Branch; Kaohsiung Taiwan

10. Onkologicka Klinika; Lekarska Fakulta Univerzity Palackeho a Fakultni Nemocnice; Olomouc Czech Republic

11. Hospital General de Elche; Elche Spain

12. Mayo Clinic; Rochester Minnesota USA

Funder

Merrimack Pharmaceuticals

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpt.720/fullpdf

Reference27 articles.

1. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours;Gabizon;Drugs,1997

2. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.;Greish;Methods Mol. Biol.,2010

3. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.;Wang-Gillam;Lancet,2016

4. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.;Xie;Clin. Pharmacol. Ther.,2002

5. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.;Gupta;Cancer Res.,1994

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315);Journal of Clinical Oncology;2024-09-10

2. Quantitative determination of liposomal irinotecan and SN-38 concentrations in plasma samples from children with solid tumors: Use of a cryoprotectant solution to enhance liposome stability;Journal of Chromatography B;2024-09

3. Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancreatic adenocarcinoma (NASOX): A multicenter phase I/IIa study;European Journal of Cancer;2024-09

4. Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial;The Lancet Gastroenterology & Hepatology;2024-08

5. Preclinical Pediatric Molecular Analysis for Therapy Choice (MATCH);2024-07-23